EW logo

Edwards Lifesciences

EW · What the business does, what can go wrong, and how options sellers approach it

What it does

Edwards Lifesciences makes medical devices for people with structural heart disease, which means problems with the heart's valves and related structures. It was spun off from Baxter International in 2000 and is now a focused heart-valve company.

Its best-known products are transcatheter aortic valves, which are delivered through a catheter rather than open-heart surgery. It also makes surgical tissue heart valves and a growing set of devices for the mitral and tricuspid valves.

How it makes money

Edwards sells devices to hospitals and heart centers. Each valve procedure uses a single-use implant, so revenue rises with the number of procedures performed.

Newer products often need clinical trial data, regulatory approval and reimbursement decisions before they can be widely used. Those steps shape how fast a new device contributes to sales.

Why investors own it

  • Long-term demand: Valve disease is more common in older people, and many patients go undiagnosed or untreated.
  • Shift to less invasive care: Catheter-based procedures can expand the pool of patients who are treated.
  • Innovation: Heavy research spending supports a pipeline in mitral and tricuspid therapies.
  • Specialized expertise: Clinical evidence, surgeon training and hospital relationships create barriers for competitors.

What can go wrong

  • Competitors could pressure pricing or share.
  • Reimbursement or coverage changes could affect procedure volumes.
  • Regulatory delays, recalls or weak trial results can hurt a product line.
  • Revenue is concentrated in one product family.
  • Hospital capacity limits and currency swings can affect results.

What to watch

  • Transcatheter aortic valve growth
  • Mitral and tricuspid adoption
  • Trial readouts and regulatory decisions
  • Reimbursement updates
  • Gross margin and research spending
  • Competitor launches

Options income angle

Options on EW are usually liquid for a large-cap healthcare stock, across many strikes and expirations. Spreads and open interest vary by strike, so check them first.

Implied volatility tends to rise ahead of quarterly earnings, trial results, regulatory decisions and competitor news. It often falls afterward.

One caution for premium sellers: this stock can move sharply on a single data release or guidance change. A short call may cap gains in a rally, and a short put can lead to owning shares after a sudden drop.

What the latest 10-K says

A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 25, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The filing in brief

Edwards Lifesciences grew net sales to $6.1 billion in 2025, an increase of $628.1 million, led by its transcatheter heart valve products. Net income and diluted earnings per share still fell, because of higher personnel costs, investment impairments and litigation expenses. The filing also highlights hospital capacity limits and a large, unresolved IRS tax dispute.

How the business did

  • Net sales were $6,067.6 million, up 11.5%. The United States rose 10.5%, Europe 14.8% and Rest of World 14.0%.
  • Transcatheter aortic valve replacement (TAVR, replacing a heart valve through a catheter) sales were $4,487.7 million, up 9.3%. Mitral and tricuspid therapies (TMTT) were $550.6 million, up 56.4%, on higher PASCAL and EVOQUE sales. Surgical was $1,029.3 million, up 4.9%.
  • Gross profit rose, but gross margin fell on higher operational expenses. Certain legal settlement and litigation expenses were $325.4 million, versus $40.4 million in 2024. A loss on impairment of $146.9 million related to a promissory note investment and a decision not to exercise an option to acquire one of its VIE investments.
  • The effective tax rate was 17.0%, versus 9.8% in 2024. The filing cites Pillar Two, a global minimum tax, which added approximately $19.1 million of tax expense.
  • Operating cash flow was $1,595.2 million. The company repurchased 11.7 million shares at an aggregate cost of $884.7 million. It completed the sale of a non-core product group on December 18, 2025, after selling Critical Care to BD in 2024. Both are shown as discontinued operations.

Risks specific to this company

  • Hospital capacity: Procedures depend on hospital staff and catheterization labs. The filing says constrained volumes have already occurred because more products, including the company's own, compete for the same facilities and staff.
  • IRS transfer pricing dispute: The IRS issued a notice of deficiency seeking additional tax of $269.3 million for 2015 through 2017, before interest. The company plans to contest it in court and has made deposits of $75 million and $305.1 million. Royalty transactions for 2018 through 2025 remain under examination.
  • Tax incentives: Certain foreign tax incentives, whose primary benefit expires in 2032, reduced cash tax expense by $93.9 million in 2025, versus $249.3 million in 2024.
  • Reimbursement: Hospitals rely on payors to cover TAVR procedures. The filing names restrictive requirements in the U.S. national coverage determination for TAVR as a limit on marketing, and warns payors may cut reimbursement.
  • Tariffs and EU access: A U.S. Section 232 investigation covers medical device imports. Separately, an unresolved EU-Switzerland Mutual Recognition Agreement could affect devices the company imports into the EU through its Swiss offices.
  • Suppliers: Certain supplies come from single sources, and replacing a vendor requires regulatory work. Bovine tissue used in valves comes only from the United States and Australia.

What management is watching

  • R&D and growth plans: The company invested 18% of net sales in research and development. It aims to treat non-valvular conditions such as heart failure, and R&D rose on implantable heart failure management innovations.
  • Pipeline: Recent events include FDA approval of SAPIEN 3 for severe aortic stenosis patients without symptoms and FDA and CE Mark approval of the SAPIEN M3 mitral valve system. Enrollment in the CLASP IIF trial is complete.
  • Spending: Capital expenditures are expected to be approximately $280.0 million in 2026. Contingent milestone payments could be up to $1.1 billion if all conditions are met.
  • Financial position: A $750.0 million revolving credit facility had no amounts outstanding, and $600.0 million of 4.3% senior notes are due June 15, 2028. Remaining repurchase authority is $2.0 billion.
  • Evidence: Management stresses clinical, economic and quality-of-life data, which it says patients, clinicians and payors increasingly expect.

What the latest 10-Q says

A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed November 4, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The quarter in brief

Edwards reported net sales of $1,715.5 million for the third quarter, up 10.5%, led by its newer mitral and tricuspid heart valve products. Profit for the first nine months was held back by a California tax change and a large write-off of a research asset, so diluted earnings per share were $1.61 against $1.67 a year earlier. The filing also details a widening IRS transfer pricing dispute that the company says could be material if it loses.

How the business did

  • Sales: Third-quarter net sales were $1,715.5 million versus $1,553.1 million a year earlier. Nine-month net sales were $5,105.1 million versus $4,498.0 million, up 13.5%, driven mainly by TAVR (transcatheter aortic valve replacement) and TMTT (transcatheter mitral and tricuspid therapies).
  • Segments: TAVR sales were $1,241.6 million, up 8.0%. TMTT sales were $209.5 million, up 44.3%, on PASCAL, EVOQUE and SAPIEN M3. Surgical sales were $264.4 million, up 2.5%. By region, Rest of World rose 20.2%, the United States 11.0% and Japan 2.2%.
  • Profit: Third-quarter operating income was $299.1 million versus $307.1 million, after a $220.2 million impairment, mostly the full write-off of an in-process research and development asset. Quarterly diluted earnings per share were $0.53 versus $0.50. The nine-month effective tax rate was 31.2% versus 16.1%, mainly because of a $174.4 million valuation allowance (a reserve against a tax asset the company no longer expects to use) after California limited the use of business tax credits. Nine-month investment impairments were $163.6 million.
  • Cash and capital return: Nine-month operating cash flow was $1,266.0 million, up $121.7 million on lower tax payments. The company repurchased 8.5 million shares for $696.6 million and had approximately $1.3 billion of repurchase authority left. Nothing was drawn on its $750.0 million credit facility.

What management is watching

  • IRS disputes: In early October 2026 the IRS issued a report proposing tax increases for 2018, 2019 and 2020 of $167.0 million, $112.5 million and $144.5 million, plus 40% penalties. The company says these overstate its liability, will file a protest by November 20, 2026, and has recorded no additional amounts. It says an adverse outcome could materially affect its financial statements.
  • Spending: R&D rose on aortic transcatheter valve and mechanical circulatory support (heart pump) technology, and SG&A rose on headcount and commercial activity. Potential future acquisition milestone payments could total up to $332.5 million.
  • Product and coverage catalysts: Medicare broadened TAVR coverage in September 2026, including certain patients without symptoms. FDA approvals continued, including PASCAL Precision for tricuspid repair in October 2026.
  • Tax and trade: The company expects Pillar Two global minimum tax rules to add approximately $45.0 million of tax expense in 2026 before offsets. It says it cannot predict tariff outcomes or whether it can offset them.

Follow EW in Kortex

The Kortex app shows EW's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.